NMTR - NMTR STOCK NEWS

9 Meters Biopharma (NASDAQ:NMTR) has announced a public offering of 30,000,000 shares of common stock at a price of $1.00 per share, aiming to raise $30 million before expenses. The underwriters are granted an option to purchase up to 4,500,000 additional shares within 30 days. The offering, conducted under a previously effective registration statement, is expected to close on April 5, 2021. Funds raised will support the advancement of NM-002 and larazotide in clinical trials targeting rare gastroenterological diseases.

9 Meters Biopharma (NASDAQ: NMTR) has outlined its plans to initiate a Phase 2 trial for NM-002 targeting short bowel syndrome (SBS) in Q2 2021, following positive feedback from the FDA. The company has reported successful topline data from its Phase 1b/2a trial in December 2020, indicating enhanced quality of life for SBS patients. Financially, the company raised over $58 million in 2020. A Phase 3 analysis for larazotide in celiac disease is expected in 2022 due to enrollment delays caused by COVID-19. The firm’s cash on hand as of December 31, 2020, was approximately $37.9 million.

9 Meters Biopharma (NASDAQ: NMTR) announces a key opinion leader webinar on March 23, 2021, to discuss short bowel syndrome (SBS) and provide an update on the NM-002 development program. The event will feature KOLs and management presentations covering topics like the clinical impact of chronic diarrhea, potential treatment paradigms with GLP-1, and a recap of Phase 1b/2a results. NM-002, a long-acting GLP-1 receptor agonist, aims to improve outcomes for SBS patients. Following the presentations, a live Q&A session will engage attendees.

9 Meters Biopharma (NASDAQ:NMTR) announced its participation in two upcoming investor conferences in March 2021. The first event is the Oppenheimer 31st Annual Healthcare Conference on March 17, where CEO John Temperato will present from 8:00 - 8:30 AM (ET). The second is the Maxim Group 2021 Emerging Growth Virtual Conference, also on March 17-18, featuring an on-demand presentation by Temperato. Investors can join via webcast or request one-on-one meetings. For further details, visit their website.

9 Meters Biopharma (NASDAQ:NMTR) announced that its Chief Medical Officer, Dr. Patrick Griffin, will present at a virtual NIH workshop on March 18-19, 2021, focused on celiac disease. The workshop aims to address research gaps in the field. Dr. Griffin will discuss larazotide, the only therapeutic candidate for celiac disease in Phase 3 trials, designed to alleviate symptoms related to gluten ingestion. The NIH initiative follows requests from Congress to bolster celiac disease research and will highlight findings post-workshop.

9 Meters Biopharma (NASDAQ: NMTR) appointed Michael Rice to its board of directors, enhancing its governance with his extensive background in healthcare investment. Rice is the co-founder of LifeSci Advisors and previously held significant roles at Canaccord Adams and Bank of America. Dr. Mark Sirgo, chairman, expressed confidence in Rice's experience to aid the company’s clinical programs targeting celiac and short bowel disease. 9 Meters is advancing NM-002 into a Phase 2 trial for short bowel syndrome and evaluating larazotide in a Phase 3 trial for non-responsive celiac disease.

9 Meters Biopharma (Nasdaq:NMTR) has announced that CEO John Temperato will present at the BIO CEO & Investor Conference from February 16-18, 2021. The presentation will provide a corporate overview and will be available on demand until March 20, 2021. Interested investors can request one-on-one meetings through the BIO system or contact LifeSci Advisors. 9 Meters Biopharma focuses on gastroenterology and is advancing NM-002 for short bowel syndrome and larazotide for non-responsive celiac disease.

9 Meters Biopharma (NASDAQ: NMTR) has partnered with the European Biomedical Research Institute of Salerno (EBRIS) to advance larazotide, a tight junction modulator, into a Phase 1 study in Australia. This initiative aims to assess the safety and tolerability of larazotide in lung tissue, particularly for treating acute respiratory distress (ARD) and potential COVID-19 complications. The Phase 1 study is expected to commence in 2021, with possibilities for further clinical development based on the results.

9 Meters Biopharma (NASDAQ: NMTR) announced the closing of an underwritten public offering of 53,076,924 shares at $0.65 per share, yielding approximately $32 million in net proceeds. These funds will support the clinical development of NM-002 for short bowel syndrome and larazotide for celiac disease, along with general corporate purposes. The offering was conducted under an effective shelf registration statement.